FY2026 EPS Estimates for Celcuity Boosted by HC Wainwright

Key Points

• HC Wainwright has raised its FY2026 earnings per share estimate for Celcuity to ($3.88), improving from a previous estimate of ($4.11), while maintaining a "Buy" rating with a price target of $50.00.
• Celcuity's stock has shown significant interest from institutional investors, with 63.33% of the stock currently held by such entities and considerable stake increases reported by multiple funds.
• The stock has experienced notable trading activity, with a recent sale by Director David Dalvey of 100,000 shares for approximately $4.4 million, resulting in a significant decrease in his ownership.

Celcuity, Inc. (NASDAQ:CELC - Free Report) - HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Celcuity in a note issued to investors on Monday, July 28th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($3.88) per share for the year, up from their prior forecast of ($4.11). HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity's FY2027 earnings at $0.81 EPS, FY2028 earnings at $4.05 EPS and FY2029 earnings at $7.13 EPS.

CELC has been the subject of a number of other reports. Stifel Nicolaus initiated coverage on shares of Celcuity in a research report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price target on shares of Celcuity in a research report on Monday, July 28th. Finally, Leerink Partners boosted their price target on shares of Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a research report on Monday, July 28th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Celcuity currently has a consensus rating of "Buy" and an average target price of $39.20.

Celcuity Stock Up 2.5%

Shares of CELC stock traded up $0.99 on Thursday, reaching $40.90. 1,032,272 shares of the stock were exchanged, compared to its average volume of 540,743. The company has a current ratio of 6.61, a quick ratio of 6.61 and a debt-to-equity ratio of 1.14. The business's 50 day moving average price is $15.25 and its 200 day moving average price is $12.30. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -13.42 and a beta of 0.68. Celcuity has a twelve month low of $7.57 and a twelve month high of $46.42.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.09.

Hedge Funds Weigh In On Celcuity

Large investors have recently bought and sold shares of the stock. AlphaQuest LLC raised its stake in shares of Celcuity by 176.3% in the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock valued at $95,000 after acquiring an additional 4,522 shares during the period. Rhumbline Advisers raised its stake in shares of Celcuity by 8.9% in the 1st quarter. Rhumbline Advisers now owns 42,194 shares of the company's stock valued at $427,000 after acquiring an additional 3,439 shares during the period. Baker BROS. Advisors LP raised its stake in shares of Celcuity by 59.0% in the 1st quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company's stock valued at $43,046,000 after acquiring an additional 1,579,182 shares during the period. Paloma Partners Management Co purchased a new position in shares of Celcuity in the 1st quarter valued at $215,000. Finally, Tema Etfs LLC purchased a new position in shares of Celcuity in the 1st quarter valued at $158,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 100,000 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the transaction, the director owned 125,000 shares of the company's stock, valued at approximately $5,497,500. This represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 15.78% of the stock is owned by corporate insiders.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.